Complications of Endovascular Treatment of Peripheral Congenital Vascular Malformations

Chapter

Abstract

Interventional procedures in the management of congenital vascular malformations (CVM) have enjoyed rapid advances in the past two decades. This has followed advances in related fields such as diagnostic ultrasound, magnetic resonance imaging (MRI), histopathology and molecular genetics. Endovascular procedures using a variety of embolic and sclerosing agents have replaced surgery as the preferred treatment option. The new interventional techniques have shown superior results to excisional surgery and have significantly reduced the need for aggressive surgical procedures. Interventional techniques are performed under fluoroscopic and/or duplex ultrasound (DUS) guidance, and advances in these imaging modalities have tremendously helped with a better management of vascular anomalies.

Notes

Acknowledgements

The authors thank Prof. BB Lee for providing the figures used in this chapter.

References

  1. 1.
    Upton J, Taghinia A. Special considerations in vascular anomalies: operative management of upper extremity lesions. Clin Plast Surg. 2011;38:143–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Australas J Dermatol. 2002;43:43–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Wong K, Chen T, Connor DE, Behnia M, Parsi K. Basic physiochemical and rheological properties of detergent sclerosants. Phlebology. 2015;30:339–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Connor DE, Cooley-Andrade O, Goh WX, Ma DD, Parsi K. Detergent sclerosants are deactivated and consumed by circulating blood cells. Eur J Vasc Endovasc Surg. 2015;49:426–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Cavezzi A, Parsi K. Complications of foam sclerotherapy. Phlebology. 2012;27(Suppl 1):46–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim B, Somia N, Pereira J, Parsi K. Open access sclerotherapy: an alternative technique to treat complex venous malformations. Dermatol Surg. 2014;40:802–5.PubMedGoogle Scholar
  7. 7.
    Donnelly LF, Bisset 3rd GS, Adams DM. Marked acute tissue swelling following percutaneous sclerosis of low-flow vascular malformations: a predictor of both prolonged recovery and therapeutic effect. Pediatr Radiol. 2000;30:415–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol. 2004;15:431–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008;34:1299–313.PubMedGoogle Scholar
  10. 10.
    Ogita S, Tsuto T, Nakamura K, Deguchi E, Iwai N. OK-432 therapy in 64 patients with lymphangioma. J Pediatr Surg. 1994;29:784–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Park HS, Do YS, Park KB, et al. Clinical outcome and predictors of treatment response in foam sodium tetradecyl sulfate sclerotherapy of venous malformations. Eur Radiol. 2016;26:1301–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Yamaki T, Nozaki M, Sakurai H, et al. Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg. 2008;47:578–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Parsi K, Hannaford P. Intra-arterial injection of sclerosants: report of three cases treated with systemic steroids. Phlebology. 2015;31:241–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Tran D, Parsi K. Veno-arteriolar reflex vasospasm of small saphenous artery complicating sclerotherapy of the small saphenous vein. Austr N Z J Phleb. 2007;10:29–32.Google Scholar
  15. 15.
    Lee KB, Kim DI, Oh SK, et al. Incidence of soft tissue injury and neuropathy after embolo/sclerotherapy for congenital vascular malformation. J Vasc Surg. 2008;48:1286–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Tan KT, Simons ME, Rajan DK, Terbrugge K. Peripheral high-flow arteriovenous vascular malformations: a single-center experience. J Vasc Interv Radiol. 2004;15:1071–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy. Pediatr Radiol. 2012;42:1080–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63:689–702.CrossRefPubMedGoogle Scholar
  19. 19.
    Horbach SE, Rigter IM, Smitt JH, et al. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137:244–56.CrossRefPubMedGoogle Scholar
  20. 20.
    Ogita S, Tsuto T, Nakamura K, et al. OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg. 1996;31:477–80.CrossRefPubMedGoogle Scholar
  21. 21.
    Karavelioglu A, Temucin CM, Tanyel FC, et al. Sclerotherapy with bleomycin does not adversely affect facial nerve function in children with cervicofacial cystic lymphatic malformation. J Pediatr Surg. 2010;45:1627–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Marrocco-Trischitta MM, Guerrini P, Abeni D, Stillo F. Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation. Dermatol Surg. 2002;28:153–5.PubMedGoogle Scholar
  23. 23.
    Cordero-Schmidt G, Wallenstein MB, Ozen M, et al. Pulmonary hypertensive crisis following ethanol sclerotherapy for a complex vascular malformation. J Perinatol. 2014;34:713–5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Park HS, Do YS, Park KB, et al. Ethanol embolotherapy of hand arteriovenous malformations. J Vasc Surg. 2011;53:725–31.CrossRefPubMedGoogle Scholar
  25. 25.
    Do YS, Kim YW, Park KB, et al. Endovascular treatment combined with emboloscleorotherapy for pelvic arteriovenous malformations. J Vasc Surg. 2012;55:465–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Do YS, Park KB, Park HS, et al. Extremity arteriovenous malformations involving the bone: therapeutic outcomes of ethanol embolotherapy. J Vasc Interv Radiol. 2010;21:807–16.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee BB, Baumgartner I, Berlien HP, et al. Consensus Document of the International Union of Angiology (IUA)-2013. Current concept on the management of arterio-venous management. Int Angiol. 2013;32:9–36.PubMedGoogle Scholar
  28. 28.
    Park KB, Do YS, Kim DI, et al. Predictive factors for response of peripheral arteriovenous malformations to embolization therapy: analysis of clinical data and imaging findings. J Vasc Interv Radiol. 2012;23:1478–86.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim JS, Nam MH, Do YS, et al. Efficacy of milrinone versus nitroglycerin in controlling pulmonary arterial hypertension induced by intravenous injections of absolute ethanol in anesthetized dogs. J Vasc Interv Radiol. 2010;21:882–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Ko JS, Kim JA, Do YS, et al. Prediction of the effect of injected ethanol on pulmonary arterial pressure during sclerotherapy of arteriovenous malformations: relationship with dose of ethanol. J Vasc Interv Radiol. 2009;20:39–45. quiz 45CrossRefPubMedGoogle Scholar
  31. 31.
    Shin BS, Do YS, Cho HS, et al. Effects of repeat bolus ethanol injections on cardiopulmonary hemodynamic changes during embolotherapy of arteriovenous malformations of the extremities. J Vasc Interv Radiol. 2010;21:81–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg. 1995;30:1282–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Bush RG, Derrick M, Manjoney D. Major neurological events following foam sclerotherapy. Phlebology. 2008;23:189–92.CrossRefPubMedGoogle Scholar
  34. 34.
    Rabe E, Breu FX, Cavezzi A, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29:338–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Lv X, Wu Z, Jiang C, et al. Complication risk of endovascular embolization for cerebral arteriovenous malformation. Eur J Radiol. 2011;80:776–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Hartmann A, Pile-Spellman J, Stapf C, et al. Risk of endovascular treatment of brain arteriovenous malformations. Stroke. 2002;33:1816–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Yun WS, Kim YW, Lee KB, et al. Predictors of response to percutaneous ethanol sclerotherapy (PES) in patients with venous malformations: analysis of patient self-assessment and imaging. J Vasc Surg. 2009;50:581–9. 589 e581CrossRefPubMedGoogle Scholar
  38. 38.
    Parsi K, Exner T, Connor DE, et al. The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro. Eur J Vasc Endovasc Surg. 2008;36:216–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of DermatologySt. Vincent’s Hospital, University of New South WalesSydneyAustralia
  2. 2.Sungkyunkwan University, School of Medicine and Samsung Medical CenterSeoulSouth Korea

Personalised recommendations